Results 131 to 140 of about 41,587 (192)

Short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval: a target trial emulation. [PDF]

Eur J Clin Pharmacol
Chen X, Liu Y, Wei W, Xia X, Wu X, Lu X, Hu G, Lu S, Shen Y.   +8 more
europepmc   +1 more source

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial. [PDF]

Front Cardiovasc Med
Schäfer A, Großhennig A, Theis L, Schindler C, Grahl E, Stichtenoth DO, König T, Geller WA, Schmidt HHJG, Bavendiek U, Bauersachs J.   +10 more
europepmc   +1 more source

A hierarchical risk assessment framework for head-to-head comparison of statin safety profiles in Chinese patients. [PDF]

Sci Rep
Tsui L, Wang D, Fan C, Shi C.
europepmc   +1 more source

Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components. [PDF]

Clin Pharmacol Drug Dev
Lee S, Khwarg J, Bae S, Park DM, Park H, Lee S, Yu KS.   +6 more
europepmc   +1 more source

Comparative pharmacokinetics of a candesartan/amlodipine/atorvastatin fixed-dose combination 8 mg/5 mg/10 mg versus separate tablets in healthy subjects: a partial replicated crossover study. [PDF]

Transl Clin Pharmacol
Kim SY, Kwak YG, Kim MG, Moon SJ.
europepmc   +1 more source

Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. [PDF]

Sci Rep
Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM.   +3 more
europepmc   +1 more source

Coenzyme Q10 protects against atorvastatin-induced hepatotoxicity via attenuation of oxidative stress and functional modulation of CYP3A1. [PDF]

BMC Pharmacol Toxicol
Abdel-Rasol MA, Anwar MS, Taha HA, El-Sayed WM, AbdelRaouf K.   +4 more
europepmc   +1 more source

Differential effects of fresh and black garlic extracts on oxidative stress regulation and anti-inflammatory response properties in human HepG2 cells: An <i>in vitro</i> study. [PDF]

Front Pharmacol
Almughamisi M, Amer F, Alqahtani NK, Felemban AH, Jawharji MT, Hafiz HA, Wazzan H, Altuwairki D, Alharbi HF, Algheshairy RM, Altalhi R, Qahl SH, Alzahrani MS, Abu Ali OA, Sami R, Izmirly AM.   +15 more
europepmc   +1 more source

Mechanistic insights into atorvastatin-induced hepatotoxicity: molecular pathways, clinical relevance, and strategies for safer personalized therapy. [PDF]

Clin Exp Med
Abdel-Rasol MA, El-Sayed WM.
europepmc   +1 more source

Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge. [PDF]

Fundam Clin Pharmacol
Bertin B, Lacotte V, Cracowski JL, Gaiffe A, Dumortier J, Vial T.   +5 more
europepmc   +1 more source